Skip Navigation LinksTrillium Health Partners > Patient Quality and Safety > Systemic Treatment Administration for Pembrolizumab, Nivolumab and Panitumumab

 Systemic Treatment Administration for Pembrolizumab, Nivolumab and Panitumumab

At Trillium Health Partners (THP), our top priority is the delivery of high quality patient care. In June 2018, an internal review by THP revealed potential issues related to the administration of three (3) three systemic treatment drugs (Pembrolizumab, Nivolumab and Panitumumab – low volume, high concentration medications) where more than expected amounts of the drug remained in the intravenous (IV) tubing.

THP took immediate action to assess the potential impact and ensure that all patients receive their full intended medication dose. THP also changed the way these drugs were administered to ensure going forward optimal use of the drug is received.

Cancer Care Ontario was also notified and initiated a plan to work with all hospital partners in Ontario and do a thorough root cause analysis to understand the factors that may have contributed to this issue.

THP has contacted all patients and families who may have been impac​ted. THP oncologists and the Quality Department thoroughly reviewed every single patient that received the medications in question. Following the review it was determined that no patients required supplementary treatment.

We regret any additional anxiety or concern this information may cause patients and their loved ones. For anyone with questions related to chemotherapy treatments at THP, please contact Patient Relations at 905-848-7367.

Media Relations:
Catherine Pringle
Director, Communications
Catherine.Pringle@thp.ca
416-358-7201

Additional Resources:
Cancer Care Ontario Statement